News + Filings Holdings
All
13F
13D/G
Other
|
|
Bain Capital Life Sciences Fund II, L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 12/05/2022 |
3
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 3 on Solid Biosciences Inc. |
| 11/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/16/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/14/2022 |
SC 13D/A
| Bain Capital Life Sciences Fund II, L.P. reports a 4.8% stake in MERSANA THERAPEUTICS, INC. |
| 02/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/14/2022 |
SC 13G/A
| Bain Capital Life Sciences Fund II, L.P. reports a 4.9% stake in Xilio Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 02/08/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/03/2022 |
SC 13D/A
| Bain Capital Life Sciences Fund II, L.P. reports a 4.5% stake in MERSANA THERAPEUTICS, INC. |
| 12/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/05/2021 |
3
| Bain Capital Life Sciences Investors, LLC (10% Owner) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 11/05/2021 |
SC 13G
| Bain Capital Life Sciences Fund II, L.P. reports a 5.1% stake in Xilio Therapeutics, Inc. |
| 09/24/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/03/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/04/2021 |
SC 13D
| Bain Capital Life Sciences Fund II, L.P. reports a 5.6% stake in Nuvalent, Inc. |
| 05/17/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 03/17/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/12/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/14/2020 |
SC 13G
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for Syros Pharmaceuticals, Inc. |
| 11/12/2020 |
SC 13D
| Bain Capital Life Sciences Fund II, L.P. reports a 5.8% stake in ATEA PHARMACEUTICALS, INC. |
| 08/13/2020 |
SC 13G
| Bain Capital Life Sciences Fund II, L.P. has filed a Schedule 13D for ARYA Sciences Acquisition Corp III |
| 07/20/2020 |
SC 13G
| Bain Capital Life Sciences Fund II, L.P. reports a 6.3% stake in Therapeutics Acquisition Corp. |
| 04/17/2020 |
SC 13D
| Bain Capital Life Sciences Fund II, L.P. reports a 5.2% stake in MERSANA THERAPEUTICS, INC. |
| 12/30/2019 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/09/2019 |
D
| Form D - Notice of Exempt Offering of Securities: |
|
|